Cargando…
Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma
Lenvatinib is a multi-kinase inhibitor approved as a first-line treatment for patients with unresectable advanced hepatocellular carcinoma (HCC). However, its response rate is unsatisfactory, primarily due to the acquisition of resistance, which limits its clinical significance for treating patients...
Autores principales: | Miyazaki, Katsuki, Morine, Yuji, Xu, Caiming, Nakasu, Chiharu, Wada, Yuma, Teraoku, Hiroki, Yamada, Shinichiro, Saito, Yu, Ikemoto, Tetsuya, Shimada, Mitsuo, Goel, Ajay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954241/ https://www.ncbi.nlm.nih.gov/pubmed/36831279 http://dx.doi.org/10.3390/cells12040612 |
Ejemplares similares
-
Impact of apparent diffusion coefficient on prognosis of early hepatocellular carcinoma: a case control study
por: Yamada, Shinichiro, et al.
Publicado: (2023) -
Inhibition of the VEGF signaling pathway attenuates tumor-associated macrophage activity in liver cancer
por: Okikawa, Shohei, et al.
Publicado: (2022) -
Impact of L-type amino acid transporter 3 on the prognosis of hepatocellular carcinoma
por: Selenge, Baasansuren, et al.
Publicado: (2022) -
Clinical impact of myosteatosis measured by magnetic resonance imaging on long-term outcomes of hepatocellular carcinoma after radical hepatectomy
por: Yoshikawa, Kozo, et al.
Publicado: (2023) -
An exosome-based liquid biopsy signature for pre-operative identification of lymph node metastasis in patients with pathological high-risk T1 colorectal cancer
por: Miyazaki, Katsuki, et al.
Publicado: (2023)